The invention relates to compounds of general formula Iwherein R1, R2, R3, R4, m and n are defined as defined herein, and pharmaceutically acceptable salts, hydrates, or solvates thereof, for use -alone or in combination with one or more other pharmaceutically active compounds- in therapy, as JAK kinase and protein tyrosine kinase inhibitors for preventing, treating or ameliorating diseases and complications thereof, including, for example, psoriasis, atopic dermatitis, rosacea, lupus, multiple sclerosis, rheumatoid arthritis, Type I diabetes, asthma, cancer, autoimmune thyroid disorders, ulcerative colitis, Crohn's disesase, Alzheimer's disease, leukaemia, eye diseases such as diabetic retinopathy and macular degeneration as well as other autoimmune diseases and indications where immunosuppression would be desirable for example in organ transplantation.本發明係關於通式I化合物其中R1、R2、R3、R4、m及n係如本文所定義，及其醫藥學上可接受之鹽、水合物或溶劑合物，其單獨或與一或多種其他醫藥活性化合物組合用於治療，其作為JAK激酶及蛋白質酪胺酸激酶抑制劑用於預防、治療或改善疾病及其併發症，包括例如牛皮癬、異位性皮炎、紅斑痤瘡、狼瘡、多發性硬化症、類風濕性關節炎、I型糖尿病、哮喘、癌症、自體免疫甲狀腺病症、潰瘍性結腸炎、克羅恩氏病(Crohn's disesase)、阿茲海默氏症(Alzheimer's disease)、白血病、諸如糖尿病性視網膜病變及黃斑變性之眼睛疾病、以及其他將需要免疫抑制之自體免疫疾病及適應症，例如在器官移植中。
